There is evidence for a role for IGF-I in the endocrine control of human fetal growth despite the low serum IGF-I concentrations. The formation in serum of binary complexes between IGF-I or -11 and either of six IGF binding proteins (IGFBP-1 to -6) and, in particular, of long-lived ternary complexes between IGF-I or -11, IGFBP-3, and acid-labile subunit is thought to regulate IGF-I bioavailability by increasing its serum half-life. The present study assesses the bioavailability of circulating IGF-I in 19-to 35-wk gestation human fetuses in utem I) by quantitative RIA measurements of IGF and IGFBP in serum and 2) by examining whether serum proteolysis of IGFBP-3 may further increase IGF-I bioavailability. Fetal serum concentrations of IGFBP-3, IGF-I, and IGF-I1 were low with marked or only modest increases with gestational age ( p < 0.001, p < 0.005, and p < 0.05, respectively). The mean molar ratio between IGF-I plus -11 and IGFBP-3 demonstrated a molar excess of IGF (50%) similar to that in adolescents but in contrast to the 1:l molar ratio in adults. The median IGFBP-2 concentration was 3-fold elevated to a molar concentration similar to that of IGFBP-3 (adult serum displays 10-fold higher IGFBP-3 concentrations).
IGF-I and IGF-I1 are important paracrinelautocrine fetal growth factors with potential actions a s early as during human embryogenesis (1) (2) (3) (4) (5) . In addition, IGF-I may be an important endocrine growth factor regulating generalized
The median serum IGFBP-1 concentration was not elevated as previously reported in newborns. IGFBP-3 protease activity was not increased in fetal serum, in contrast to pregnancy serum and amniotic fluid. Nevertheless, IGFBP-3 protease activity did interfere with IGFBP-3 determinations by Western ligand blotting, and IGFBP-1 and IGFBP-2 levels obtained by this technique did not correlate with concentrations determined by RIA, stressing the importance of quantitative IGFBP measurements. In summary, increased IGF-I bioavailability in the human fetus is suggested by the molar excess of IGF over IGFBP-3 and the increase in IGFBP-2, which do not form a long-lived ternary complex. The lack of suppression of fetal serum IGFBP-1 may suggest that the delivery of IGF-I to the tissues is normal. (Pedidr Res 36: 528-536, 1994) Abbreviations ALS, acid-labile subunit IGFBP, IGF binding protein at the cellular level by regulating IGF binding to the type 1 IGF receptor. In addition, IGFBP regulate the bioavailability of circulating IGF by increasing IGF half-life (17) and by modulating IGF capillary transport and tissue distribution (18, 19) . In adult human serum, IGF are predominantly bound with high affinity to IGFBP-3, which subsequently associates with an ALS to form a 150-kD ternary complex (20) . IGF are more bioavailable when bound in the 44-kD binary complex to any of the other IGFBP, which do not associate with ALS (17) . Proteolysis of IGFBP-3, demonstrated in term pregnancy serum and amniotic fluid (21) (22) (23) , may offer an additional mechanism for regulation of IGF availability, presumably by altering binary and ternary complex formation. However, the source of pregnancy IGFBP-3 protease and whether it affects the fetal compartment are not known. IGFBP-2 and IGFBP-3 levels in fetal and newborn serum have been previously determined by Western ligand blotting. This technique, however, is semiquantitative at best and may be further invalidated by the presence of proteolytic IGFBP fragments (23, 24) . Specific transcapillary transport of IGFBP-1 in response to insulin makes this IGFBP particularly interesting as a carrier of IGF-I (18, 19) . IGFBP-1 concentrations are elevated in newborn serum (25) (26) (27) , suggesting that IGFBP-I accumulates and IGF-I transport may be decreased. However, it is unknown whether serum IGFBP-I levels are also elevated in the human fetus in utero.
In the present study, fetal serum concentrations of IGF-I and IGF-I1 were measured by RIA after acid chromatography. To assess IGF availability, serum IGFBP-1, -2, and -3 levels in the human fetus in utero were measured by Western ligand blotting as well as by RIA to determine the relative quantities of IGFBP. Furthermore, IGFBP-3 proteolysis, which may have additional impact on fetal IGF availability, was assessed.
METHODS

Subjects
The study included 34 human fetuses who had undergone cordocentesis due to rhesus isoimmunization of the mothers. Cordocentesis was performed according to the original technique described by Daffos et al. (28) if maternal antibody titers were higher than 1:32 or if the obstetric history included perinatal mortality or severe morbidity. Kleihauer-Betke stain was performed on all specimens, and only those that contained 100% fetal blood were included in the study. Of the 34 fetuses, nine were designated as not affected after typing of fetal blood. All blood samples were kept on ice until centrifuged. Plasma and serum were stored at -20°C until analyzed. Hematologic indices were analyzed in EDTA plasma using an automatic analyzer (Coulter Counter 5 Plus 3, Coulter Electronics, Hialeah, FL). The quantity of serum obtained from each fetus was limited, and in some cases not all analyses could be completed. The study had departmental ethical approval from the King Faisal Specialist Hospital, where the research program of rhesus isoimmunization of mothers was carried out, and informed written consent was obtained from the pregnant women.
Materials
Recombinant human IGF-I, IGF-11, des(1-3)IGF-I, and IGFBP-1 were gifts from KabiGen (Kabi-Pharmacia, Stockholm, Sweden), and these peptides were iodinated as previously described (30) . Recombinant human glycosylated and nonglycosylated IGFBP-3 were kindly donated by Celtrix (Santa Clara, CA) and nonglycosylated IGFBP-3 was iodinated as previously described (29) .
RIA
ZGF-Z and ZGF-ZI. Serum concentrations of IGF-I and IGF-I1 were determined by RIA after acid gel filtration to exclude interference of IGFBP (30) . Des(1-3)IGF-I, which has reduced affinity for IGFBP, was used as radioligand in the IGF-I RIA. The recovery of unlabeled IGF-I was 95% and the intra-and interassay coefficients of variation were 5 and 11%, respectively. The lowest detectable quantity of IGF-I was 0.02 ngltube. Crossreactivitywith insulin was less than 0.1% and with IGF-I1 less than 2%. In the IGF-I1 RIA, the least detectable quantity was 0.05 ngltube. The intra-and interassay coefficients of variation were 4 and 12%, respectively. Cross-reactivity with IGF-I was less than 2% and with insulin less than 0.1%. ZGFBP-I. Serum IGFBP-1 concentrations were determined by RIA as described by Povoa et al. (31) . The intra-and interassay coefficients of variation were 3 and 11%, respectively, and the detection limit was 3.0 pglL. Cross-reactivity with IGFBP-2 and IGFBP-3 was less than 0.5 and 0.05%, respectively. ZGFBP-2 Serum IGFBP-2 concentrations were determined by an RIA recently described by Schwander and Mary (32) . Human recombinant IGFBP-2 produced in Chinese hamster ovary cells was used as a reference preparation and as an immunogen to raise antibodies in rabbits. The sensitivity was 0.2-0.5 ngltube and the cross-reactivity with IGFBP-1 and IGFBP-3 was less than 1 and 0.01%, respectively. The intra-and interassay coefficients of variation were 6 and 12%, respectively. ZGFBP-3. IGFBP-3 concentrations were determined in serum by RIA as described earlier (33) . The intra-and interassay coefficients of variation were 3.5 and 7.3%, respectively, and the detection limit was 0.03 ngltube. Cross-reactivity with IGFBP-1 and IGFBP-2 was less than 0.05% for each.
Western Ligand Blot Analysis
Analysis of IGFBP in fetal serum by Western ligand blotting was performed as originally described by Hossenlopp et al. (34) with minor modifications. Briefly, serum (2.5 pL) was diluted with nonreducing SDS sample buffer (0.5 M Tris, pH 6.8; 69% glycerol; 4% SDS) and processed by SDS-PAGE (10% or 12% gels) at 45 V overnight. Prestained molecular weight standards were diluted in SDS sample buffer containing 1 mM DTT and processed in parallel. Separated proteins were electroblotted onto nitrocellulose filters (0.45-pm pore size) in a Hoefer Semi-dry Transphor unit (Hoefer Scientific Instruments, San Francisco, CA) at 200 mA. Filters were treated with 3% NP40 in TBS (0.1 M Tris, 0.15 M NaCI, pH 7.4) for 20 min, and blocked with 1% BSA in TBS for 120 min at 20°C. Filters were probed with '25~-labeled IGF-I1 or a mixture of '25~-labeled IGF-I and IGF-I1 in TBS containing 1% BSA (2 x lo6 cpmJ25 mL) wernight at 4°C. Thereafter, filters were washed with 0.1% Tween 20 in TBS for 1 x 20 min and 1 x 120 min. Nitrocellulose filters were dried and visualized by autoradiography. Autoradiography films were quantified by densitometry using an Ultrascan densitometer (LKB Instruments, Inc., Gaithersburg, MD). Densitometry values were corrected for interassay variability by comparison with three internal reference sera.
Western ligand blot IGFBP bands were identified by processing recombinant human IGFBP in parallel (50 ng of IGFBP-1,50 ng of IGFBP-2 (32), or 50 ng of glycosylated IGFBP-3; data not shown) or by prior immunoprecipitation with specific IGFBP antibodies as previously described (35) 
IGFBP-3 Protease Assay
Fetal serum was assessed for proteolytic activity capable of degrading radiolabeled IGFBP-3 according to the method of Lamson e t al. (29) . Briefly, 2 p L of serum were incubated with 30 000 cpm of 125~-labeled IGFBP-3 (nonglycosylated) in a total volume of 50 p L of 0.1 M Tris for 5 h at 37°C. After addition of nonreducing SDS sample buffer, the samples were processed by SDS-PAGE (15% gels) as described under Western ligand blot analysis. After electrophoresis, the SDSpolyacrylamide gel was dried in a gel dryer and exposed to x-ray film at -70°C overnight. Films were evaluated by laser densitometry (LKB Instruments, Inc.). Protease activity was defined as the absorbance of the sum of fragments of 125~-labeled IGFBP-3 with molecular mass lower than 30 kD (intact labeled peptide) relative to the total density in the lane. To correct for interassay variability, the quantity of proteolysis was expressed as a percentage of the protease activity observed with a control serum pool from healthy adults, which was given an arbitrary value of 100%.
Statistics
Values are presented as median and range, if not otherwise stated. IGF-I and IGF-I1 concentrations, which conformed to a log-normal distribution, were log transformed before regression analysis. Linear regression and multiple regression analyses were performed using a computer program (SOLO, BMDP Statistical Software, Inc., Los Angeles, CA).
RESULTS
The median gestational age of the human fetuses at the time of blood sampling was 28 wk (range, 19-35 wk). The median Hb concentration of all fetuses was 88 g/L, (range, 28-141 g/L). The percentage of the normal median Hb value for that particular week of gestation according to Rodech and Nicolini (36) was 75% (range, 21-105%). In the group of affected fetuses, the median Hb concentration was 71 g/L (28-135 g/L) or 53% (21-102%) of control values. Estimates of fetal size in utero were complicated by fetal edema in affected fetuses and complete data were not available. The median infant birth weight was 2472 g (1050-3880 g), and the median gestational age at delivery was 37 wk (27-41 wk) for the 25 affected fetuses, which were all delivered at King Faisal Specialist Hospital. All infant sizes were regarded as normal for gestational age according to national standards. Four of the affected fetuses were born dead. Infant birth weight and gestational age at delivery are not known for the nine unaffected fetuses, which were delivered at regional hospitals. Fig. 1.4 ). There was a strong positive correlation between log-transformed IGF-I and Hb (r = 0.57, p < 0.001). Multiple regression analysis revealed that IGF-I correlated with gestational age and Hb with an r value of 0.68 ( p < 0.001) ( Table 1) . Multiple regression analysis demonstrated that the birth weights of affected fetuses were correlated with serum IGF-I concentrations at the time of cordocentesis (r = 0.54, p = 0.05) when covariation with the gestational age at birth (r = 0.88, p < 0.001) and the gestational age at the time of cordocentesis (r = 0.39, p = NS) were excluded (combined r = 0 . 9 1 ,~ < 0.001) ( Table 1) .
IGF-II. The median fetal serum IGF-I1 concentration was 236 pgL (range, 135-367 pglL). IGF-I1 levels increased slightly with gestational age (r = 0.36, p < 0.05), (Table 1) . Western ligand blot analysis of fetal serum (Fig. 3) tration of 310 pgL at term (Fig. 1B) . No correlation be-revealed IGFBP bands at 40 kD and 38 kD comigrating tween IGF-I1 and Hb concentrations was displayed. with recombinant human glycosylated IGFBP-3 (data not shown) and precipitated by anti-IGFBP-3 antibody (a-IGFBP-3-gl; Fig. 4) ; at 26 kD, comigrating with recombinant human IGFBP-I (not shown); and at 24 kD, presumably representing IGFBP-4 (37). In addition, the 31-to 28-kD molecular mass range displayed at least two bands, not completely resolved, of which the upper band comigrated with recombinant human IGFBP-2 and was precipitated by a-HEC antibody as was the 40-to 38-kD doublet (a-HEC antibody has a weak affinity for IGFBP-3) (Fig. 4) To determine whether increased IGFBP-3 proteolytic activity in maternal serum and amniotic fluid also affects the fetal compartment, the IGFBP-3 proteolytic activity in fetal serum was determined. Figure 5 shows a representative protease assay of 19-to 24wk gestation human fetal sera. Densitometric analysis of all fetal sera demonstrated a median IGFBP-3 protease activity of 96% (range, 21-156%) of a control serum pool from healthy adults, which was given an arbitrary value of 100%. Human pregnant serum, by comparison, displayed an IGFBP-3 protease activity of 256% of the control serum pool (median of four determinations).
-
Stoichiometry of IGF and IGFBP Concentrations
DISCUSSION
Serum concentrations of immunoreactive IGF-I increased exponentially with gestational age in human fetuses of 19 to 35 wk gestation, whereas IGF-I1 displayed only a slight increase. Our results are in agreement with the changes in IGF-I and IGF-I1 concentrations with gestational age reported in serum obtained in utero from normal human fetuses of 15-23 (6) and 20-37 wk gestation (7), although the absolute concentrations in the latter report are somewhat higher. The predicted serum IGF-I and IGF-I1 concentrations at term are in accordance with those determined in healthy newborns, using the same assays (26) . These notions are important, because they may suggest that there was no major effect on the IGF-IGFBP axis in fetuses affected by rhesus isoimmunization in the present study.
The low serum IGF-I levels during rapid fetal growth may seem to challenge the role of IGF-I as an endocrine growth factor. However, IGF-I bioavailability in fetal serum is likely to be increased. In fetal serum, the mean IGFBP-3 concentration was 4-fold decreased relative to adult concentrations and the mean molar ratio of [IGF-I] + [IGF-11] to [IGFBP3] was 1.5:1,50% higher than that reported in adults (33, 38) . Serum IGFBP-2 concentrations, on the other hand, were 3-fold elevated. Rapid pubertal growth is also associated with an increased IGF to IGFBP-3 ratio (39). Because less IGF-I is bound by IGFBP-3, which has a 10-fold higher affinity for IGF-I GESTATIONAL AGE (WEEKS) Figure 3 . Western ligand blot analysis of serum IGFBP in 19-to 35-wk gestation human fetuses of rhesus-isoimmunized pregnancies. Fetal serum was obtained from the umbilical cord in utero and processed by SDS-PAGE under nonreducing conditions, electroblotted to nitrocellulose, and probed with a mixture of '=I-labeled IGF-I and IGF-I1 (see Methods). For the designation of bands to specific IGFBP, see Figure 4 and Methods. Laser densitometric scanning was used to quantitate the bands.
than does IGFBP-2 (40), potentially less IGF-I will be "trapped" in the ternary complex and more IGF-I will be bound by IGFBP-2 in the binary complex. Therefore, IGF-I availability is likely to be increased, given that the IGF-I half-life in the ternary complex is 15 h, compared with 0.5 h in the binary complex [based on data from adult human serum (17)l. This conclusion is in agreement with previous studies showing that the distribution of IGF between the binary and ternary complexes is altered in human (7, 41) The supernatant was processed by Western ligand blotting as described in Figure 3 and Methods.
increased fraction of total IGF in the binary complex. The increase in IGF-I availability may be even more pronounced in the early gestation human fetus because serum IGFBP-3 concentrations as well as the IGFBP-3:IGFBP-2 ratio increase with gestational age, as also previously reported (43) .
In addition to functioning as short-and longer-term storage for IGF-I, IGFBP may act as transcapillary carriers of IGF-I, regulating IGF-I availability and seques- tration in the tissues. IGFBP-1 has been suggested to act as such an IGF carrier, and this process may be increased by insulin both in rats (18, 19) and in humans (44) . IGF-I and human IGFBP-1 infused in equi-molar ratios to rats was not as potent as IGF-I alone, and human IGFBP-1 infused alone (reaching 50-fold the normal rat IGFBP-1 concentration) may block the actions of endogenous IGF (45) . It is not clear from that study, however, whether normal physiologic concentrations of rat IGFBP-1 may play a role as a transcapillary carrier of IGF-I. However, it is tempting to hypothesize that increased IGFBP-1 concentrations reported in serum from IUGR newborns (12, 26, 27) may signify an accumulation of IGFBP-1 in the circulation, resulting in decreased transport of IGF to target tissues and decreased growth. Similarly, IGFBP-1 concentrations in cord serum from term newborns have been reported to be high, although variable (12, (25) (26) (27) , which may suggest that IGF-I transport and availability are decreased immediately after birth in accordance with the temporary lack of growth. Importantly, in the rapidly growing human fetus in utero, serum IGFBP-1 concentrations, which have not previously been measured by RIA, were not generally increased. Serum IGFBP-1 expression is inhibited by insulin postnatally (46) , and IGFBP-1 concentrations are increased rapidly by shortterm fasting (4749). Whether factors like low maternal nutritional intake before delivery and restricted placental blood and nutrient flow during delivery and stress (50) may result in increased serum IGFBP-1 in the newborn is not known. IGFBP-1 and IGFBP-2 were inversely correlated with the fetal serum IGF-I concentration. These correlations are expected from the findings of increased serum IGFBP-1 and IGFBP-2 levels by Western ligand blotting and decreased IGF-I in IUGR newborns (21, 27, 43) . IGF-I has been reported to inhibit IGFBP-1 production in Hep G-2 cells (51), which, similar to the fetal liver but unlike the adult liver, display high expression of the type 1 IGF receptor (2, 52) . Because the fetal human liver is the major production site for IGFBP-1 and IGFBP-2 (14, 15), IGF-I may regulate their expression in the human fetus.
In contrast to term pregnancy serum and amniotic fluid (21-23), increased IGFBP-3 protease activity could not be demonstrated in human fetal serum. Thus, the human fetal compartment is protected from the IGFBP-3 serum protease(s) [or contains the appropriate protease inhibitor(~)], suggesting that IGFBP-3 protease(s) is not involved in regulating IGF-I availability in human fetal serum. Although not increased, IGFBP-3 proteolysis did interfere with IGFBP-3 determinations by Western ligand blotting, as demonstrated by the inverse correlation between IGFBP-3 proteolytic activity and IGFBP-3 levels determined by Western ligand blotting. The loss of IGFBP-3 detection by Western ligand blotting has been explained by decreased affinity of proteolytic IGFBP-3 fragments for radiolabeled IGF (53) . However, the interference was moderate because IGFBP-3 levels by RIA and Western ligand blotting remained significantly correlated. Furthermore, the lack of correlations between RIA and Western ligand blot determinations of IGFBP-1 and IGFBP-2 may be explained by the small quantities of IGFBP-1 in serum and the lack of resolution of the IGFBP-2 band from other IGFBP bands in the 30-kD molecular mass range (i-a. glycosylated IGFBP-4, IGFBPd, or IGFBP-6). These findings emphasize the problems of quantitation by Western ligand blotting previously demonstrated by others (23, 24) .
It is debatable whether anemic fetuses, affected by rhesus isoimmunization of the mothers, have a restricted growth rate. In a limited number of cases of rhesus isoimmunization, it was reported that a fetal Hb concentration less than 30% of normal was associated with a decreased fetal growth rate (54) . However, these findings could not be confirmed in less-affected fetuses (55) . In the present study, which included five fetuses with Hb less than 30% of normal, fetal sizes at birth were regarded as normal for gestational age, perhaps because the affected fetuses were treated with blood transfusions in utero. There was a strong positive correlation between IGF-I and Hb, which suggests that erythroblastosis and anemia are associated with decreased circulating IGF-I levels, even in less severe cases. Furthermore, there was a significant correlation between the birth weights and fetal serum IGF-I levels, regardless of when they were measured. Correlations between fetal size and serum IGF-I concentrations in utero and in the newborn have been previously reported (6, 7, (9) (10) (11) (12) . Therefore, it could be speculated that impaired growth in anemic human fetuses at least partially results from low serum IGF-I levels. In the present study, neither IGFBP-1 nor IGFBP-3 was significantly correlated with Hb, and the correlation between IGFBP-3 and Hb was due to covariation between Hb and gestational age, as revealed by multiple regression analysis.
In conclusion, increased IGF-I bioavailability in human fetal serum is suggested by the increased quantitative importance of IGFBP-2, which, in contrast to IGFBP-3, does not form a long-lived ternary complex with IGF-I and ALS. Furthermore, fetal serum IGFBP-1 concentrations were not elevated as previously reported in newborn serum, which may be of importance for the normal delivery of IGF-I to the tissues. Although the fetal circulation is not affected by increased IGFBP-3 proteolysis, as previously demonstrated in pregnancy serum and amniotic fluid, additional studies are needed to assess ternary complex formation. Finally, the present study points out some problems associated with the detection of IGFBP by Western ligand blotting and stresses the importance of IGFBP determinations by specific, quantitative techniques in fetal serum.
